Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
CAGRILINTIDE
Cagrilintide is a long-acting analogue of amylin, a hormone released by pancreatic beta cells alongside insulin. It is studied alone and as the amylin-side component of the investigational CagriSema combination.
Loading your saved choices…
CAGRILINTIDE is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If CAGRILINTIDE is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding Cagrilintide
Explore the science, research focus, and key information behind this compound.
What is Cagrilintide?+
Cagrilintide is a natural comparison point when a study moves beyond incretin pathways to include amylin biology.
What Researchers Study+
Researchers examine Amylin-receptor activity, Metabolic signalling, and Long-acting analogue research.
How Cagrilintide Works+
Cagrilintide engages amylin- and calcitonin-receptor systems involved in satiety, food intake, and gastric-emptying signals. That is a different biological route from GLP-1, which is why researchers study the two separately and together.
Research at a Glance+
Dose-responsive clinical activity was reported. A 26-week randomized phase 2 trial compared once-weekly cagrilintide with placebo and liraglutide in adults with overweight or obesity. The results establish a clinical-development signal for that product—not a guaranteed effect for research material. Read the peer-reviewed phase 2 trial. Amylin is not another name for GLP-1. Both pathways can influence food-intake and gastric signals, but they use different receptor systems. Cagrilintide is valuable precisely because it lets researchers test the amylin route on its own. Most current attention is on combinations. CagriSema research asks whether pairing cagrilintide with semaglutide produces complementary effects. A combination result cannot be assigned to cagrilintide alone without component controls.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.